Diagnosis and Current Management of Hepatocellular Carcinoma
DOI:
https://doi.org/10.37275/bsm.v8i3.945Keywords:
HCC, Hepatocellular carcinoma, Immunotherapy, TACE, Targeted therapyAbstract
Hepatocellular carcinoma (HCC) is a primary malignant liver tumor originating from hepatocytes which has a very poor prognosis and is ranked the sixth most common cancer disease in the world and is ranked third in deaths caused by cancer worldwide. Symptoms of underlying liver diseases such as hepatitis and cirrhosis often disguise the diagnosis of HCC so that most cases are discovered at an advanced stage. The examination modalities commonly used in surveillance are liver ultrasound (USG) examination and measurement of alpha levels fetoprotein (AFP) with sensitivity diagnostic up to 90%. Non-invasive imaging plays an important role in objective recognition and staging enforcement diagnosis as early as possible so that the patient's prognosis is better. Treatment for early-stage HCC can be given through curative therapy such as resection, liver transplantation, and local ablation, but disease at an advanced stage causes limited options in management where governance The current focus is on systemic therapy with a focus on a combination strategy of immunotherapy or a combination of targeted therapy with immunotherapy as the first line.
Authors
- Rivo Armanda Satria1*
- Saptino Miro2
- 1Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
- 2Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
Corresponding author Rivo Armanda Satria — rivoarmanda@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
